Press Release|Articles|December 3, 2024
Camber Pharmaceuticals Announces Addition of Decitabine for Injection
Listen
0:00 / 0:00
Key Takeaways
- Decitabine for Injection targets adult patients with myelodysplastic syndromes, including various subtypes and chronic myelomonocytic leukemia.
- The product is offered in a 50 mg single-dose vial, enhancing treatment accessibility.
Advertisement
Camber Pharmaceuticals is excited to announce the addition of Decitabine for Injection.
Decitabine for Injection is indicated for treatment of:
- adult patients with myelodysplastic syndromes (MDS)
- de novo and secondary MDS of all French-American British subtypes
- refractory anemia with excess blasts
- chronic myelomonocytic leukemia
Decitabine for Injection is available in a 50 mg Single-Dose Vial.
To find out more information on Decitabine for Injection please visit:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Polycystic Ovary Syndrome Undergoes Name Change: Polyendocrine Metabolic Ovarian Syndrome
2
Amid Mounting Pressure, FDA Commissioner Marty Makary to Resign
3
GLP-1 Receptor Agonists Linked to Improved Survival Outcomes in Breast Cancer
4
From Misdiagnosis to Advocacy: Addressing Bias and Equity in Heart Failure Management
5